Jade Biosciences, Inc. (JBIO) stock
JBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
$15.40+0.06 (+0.42%)
Close on Nov 17, 2026Market cap $979.40MP/E –Yield –
Jade Biosciences cash
Cash and short-term investments held at the end of each period.
Jade Biosciences's cash was $475.71M at Sep 30, 2026. For fiscal 2025 it was $336.16M, up 327.7% from the year before. The highest annual figure on record is $336.16M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $336.16M | +327.7% |
| FY2024 | Dec 31, 2024 | $78.60M | -35.8% |
| FY2023 | Dec 31, 2023 | $122.40M | -5.3% |
| FY2022 | Dec 31, 2022 | $129.20M | -22.8% |
| FY2021 | Dec 31, 2021 | $167.40M | +3560.6% |
| FY2020 | Dec 31, 2020 | $4.57M | +30.1% |
| FY2019 | Dec 31, 2019 | $3.51M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $475.71M | +139.2% |
| Q2 FY2026 | Jun 30, 2026 | $461.21M | +108.7% |
| Q1 FY2026 | Mar 31, 2026 | $311.30M | +308.5% |
| Q4 FY2025 | Dec 31, 2025 | $336.16M | +327.7% |
| Q3 FY2025 | Sep 30, 2025 | $198.91M | +124.2% |
| Q2 FY2025 | Jun 30, 2025 | $220.94M | +112.0% |
| Q1 FY2025 | Mar 31, 2025 | $76.20M | -23.3% |
| Q4 FY2024 | Dec 31, 2024 | $78.60M | -35.8% |
| Q3 FY2024 | Sep 30, 2024 | $88.70M | -34.4% |
| Q2 FY2024 | Jun 30, 2024 | $104.20M | -30.6% |
| Q1 FY2024 | Mar 31, 2024 | $99.30M | -16.5% |
| Q4 FY2023 | Dec 31, 2023 | $122.40M | -5.3% |
| Q3 FY2023 | Sep 30, 2023 | $135.20M | -5.2% |
| Q2 FY2023 | Jun 30, 2023 | $150.10M | -1.2% |
| Q1 FY2023 | Mar 31, 2023 | $118.90M | -26.2% |
| Q4 FY2022 | Dec 31, 2022 | $129.20M | -22.8% |
| Q3 FY2022 | Sep 30, 2022 | $142.60M | -21.2% |
| Q2 FY2022 | Jun 30, 2022 | $152.00M | +157.0% |
| Q1 FY2022 | Mar 31, 2022 | $161.10M | +3422.9% |
| Q4 FY2021 | Dec 31, 2021 | $167.40M | +2144.9% |
| Q3 FY2021 | Sep 30, 2021 | $180.88M | +18508.8% |
| Q2 FY2021 | Jun 30, 2021 | $59.15M | +1583.3% |
| Q4 FY2020 | Dec 31, 2020 | $4.57M | – |
| Q3 FY2020 | Sep 30, 2020 | $7.46M | – |
| Q2 FY2020 | Jun 30, 2020 | $972.00K | – |
| Q4 FY2019 | Dec 31, 2019 | $3.51M | – |
See a number that looks wrong?